HK Stock Market Move | ABBISKO-B (02256) surged by more than 5% and will announce annual performance on next Monday, with Merck's advance payment helping the company turn losses into profits.

ABBISKO-B (02256) is now up more than 5%. As of the time of writing, it has increased by 4.77% to HK$6.37, with a trading volume of HK$123.95 million. On the news front, Herui will hold a board meeting on March 3 (next Monday) to consider and approve the annual performance. The company previously announced that it expects total revenue for last year to be around RMB 504 million, an increase of approximately RMB 485 million year-on-year, with a net profit of no less than RMB 10 million for the period. In 2023, the company expects to turn losses of approximately RMB 432 million into profits, mainly due to improving cost control through increased operational efficiency; and a licensing agreement for pimicotinib (ABSK021) and an initial payment of $70 million from Merck. It is worth noting that on December 16, 2024, Herui Medicine announced that based on the approval of the China National Medical Products Administration Drug Evaluation Center, it will conduct registration clinical studies for the treatment of hepatocellular carcinoma (HCC) with paritinib. Debon Securities pointed out that this study will serve as a key basis for supporting the listing of paritinib, and also marks an important step forward for paritinib in the treatment of advanced or unresectable hepatocellular carcinoma.